Diagnosticos da America's EBIT per Share for the
three
months ended in Mar. 2026 was R$0.25.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was R$0.70.
During the past 12 months, the average EBIT per Share Growth Rate of Diagnosticos da America was -75.00% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -24.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 32.70% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 0.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Diagnosticos da America's EBIT per Share or its related term are showing as below:
BSP:DASA3'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -47.7 Med: 5.85 Max: 72.6
Current: -24.3
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Diagnosticos da America was 72.60% per year. The lowest was -47.70% per year. And the median was 5.85% per year.
BSP:DASA3's 3-Year EBIT Growth Rate is ranked worse than 86.9% of 168
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.1
vs BSP:DASA3: -24.30
Diagnosticos da America (BSP:DASA3) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Diagnosticos da America EBIT per Share Related Terms
Diagnosticos da America EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$0.70
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnosticos da America (BSP:DASA3) has a EBIT per Share of R$0.70 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Diagnosticos da America and its competitors. According to the industry distribution chart, Diagnosticos da America ranks #146 out of 168 companies in the Medical Diagnostics & Research industry, placing it in the top 86.9%.
Is Diagnosticos da America's EBIT per Share too high?
Diagnosticos da America's current EBIT per Share is R$0.70. Based on the distribution chart, Diagnosticos da America ranks #146 out of 168 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Diagnosticos da America has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diagnosticos da America's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diagnosticos da America ranks #146 out of 168 companies for EBIT per Share. This places Diagnosticos da America in the lower half of its industry. The industry median EBIT per Share is 13.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.10, based on 168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Diagnosticos da America and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnosticos da America's current EBIT per Share is R$0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnosticos da America stock overvalued right now?
Based on GuruFocus' analysis, Diagnosticos da America (BSP:DASA3) is currently considered Significantly Overvalued. The stock's GF Value™ is R$1.70, compared to a current price of R$2.70 — trading 58.8% above its estimated fair value. The current EBIT per Share is R$0.70. Diagnosticos da America's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Diagnosticos da America (BSP:DASA3), the current EBIT per Share is R$0.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diagnosticos da America (BSP:DASA3) Overvalued in 2026?
Based on GuruFocus' analysis, Diagnosticos da America stock appears to be overvalued.
The current stock price of R$2.70 is trading 58.8% above its estimated GF Value™ of R$1.70.
GuruFocus considers Diagnosticos da America to be Significantly Overvalued.
Key valuation signals for BSP:DASA3:
EBIT per Share: R$0.70
GF Value™: R$1.70 vs. price of R$2.70 (58.8% above fair value)
No single metric tells the full story. See the BSP:DASA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diagnosticos da America SA operates as a medical diagnostics company in Brazil. The company offers clinical analysis, diagnostic imaging tests, and patient service centers. It has three operating segments. Outpatient care services and care coordination includes Diagnosis and health management, Hospitals and oncology include Medical and hospital services & Foreign operations include Diagnosis. The majority is from the Hospitals and oncology segment. Geographically, it operates in Brazil and South America (Argentina, Uruguay, Chile and Colombia).
46GF Score
Get the complete analysis for BSP:DASA3
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:DASA3 has been successfully added to your 
